Colice G L, Curtis A, Deslauriers J, Heffner J, Light R, Littenberg B, Sahn S, Weinstein R A, Yusen R D
Pulmonary and Respiratory Services, Washington Hospital Center, Washington, DC, USA.
Chest. 2000 Oct;118(4):1158-71. doi: 10.1378/chest.118.4.1158.
A panel was convened by the Health and Science Policy Committee of the American College of Chest Physicians to develop a clinical practice guideline on the medical and surgical treatment of parapneumonic effusions (PPE) using evidence-based methods.
Based on consensus of clinical opinion, the expert panel developed an annotated table for evaluating the risk for poor outcome in patients with PPE. Estimates of the risk for poor outcome were based on the clinical judgment that, without adequate drainage of the pleural space, the patient with PPE would be likely to have any or all of the following: prolonged hospitalization, prolonged evidence of systemic toxicity, increased morbidity from any drainage procedure, increased risk for residual ventilatory impairment, increased risk for local spread of the inflammatory reaction, and increased mortality. Three variables, pleural space anatomy, pleural fluid bacteriology, and pleural fluid chemistry, were used in this annotated table to categorize patients into four separate risk levels for poor outcome: categories 1 (very low risk), 2 (low risk), 3 (moderate risk), and 4 (high risk). The panel's consensus opinion supported drainage for patients with moderate (category 3) or high (category 4) risk for a poor outcome, but not for patients with very low (category 1) or low (category 2) risk for a poor outcome. The medical literature was reviewed to evaluate the effectiveness of medical and surgical management approaches for patients with PPE at moderate or high risk for poor outcome. The panel grouped PPE management approaches into six categories: no drainage performed, therapeutic thoracentesis, tube thoracostomy, fibrinolytics, video-assisted thoracoscopic surgery (VATS), and surgery (including thoracotoiny with or without decortication and rib resection). The fibrinolytic approach required tube thoracostomy for administration of drug, and VATS included post-procedure tube thoracostomy. Surgery may have included concomitant lung resection and always included postoperative tube thoracostomy. All management approaches included appropriate treatment of the underlying pneumonia, including systemic antibiotics. Criteria for including articles in the panel review were adequate data provided for >/=20 adult patients with PPE to allow evaluation of at least one relevant outcome (death or need for a second intervention to manage the PPE); reasonable assurance provided that drainage was clinically appropriate (patients receiving drainage were either category 3 or category 4) and drainage procedure was adequately described; and original data were presented. The strength of panel recommendations on management of PPE was based on the following approach: level A, randomized, controlled trials with consistent results or individual randomized, controlled trial with narrow confidence interval (CI); level B, controlled cohort and case control series; level C, historically controlled series and case series; and level D, expert opinion without explicit critical appraisal or based on physiology, bench research, or "first principles."
The literature review revealed 24 articles eligible for full review by the panel, 19 of which dealt with the primary management approach to PPE and 5 with a rescue approach after a previous approach had failed. Of the 19 involving the primary management approach to PPE, there were 3 randomized, controlled trials, 2 historically controlled series, and 14 case series. The number of patients included in the randomized controlled trials was small; methodologic weaknesses were found in the 19 articles describing the results of primary management approaches to PPE. The proportion and 95% CI of patients suffering each of the two relevant outcomes (death and need for a second intervention to manage the PPE) were calculated for the pooled data for each management approach from the 19 articles on the primary management approach. (ABST
美国胸科医师学会健康与科学政策委员会召集了一个小组,采用循证方法制定关于肺炎旁胸腔积液(PPE)内科及外科治疗的临床实践指南。
基于临床意见的共识,专家小组制定了一张注释表,用于评估PPE患者预后不良的风险。预后不良风险的评估基于临床判断,即如果胸腔未得到充分引流,PPE患者可能会出现以下任何一种或全部情况:住院时间延长、全身毒性证据持续存在、任何引流操作导致的发病率增加、残余通气功能障碍风险增加、炎症反应局部扩散风险增加以及死亡率增加。该注释表使用胸腔解剖结构、胸腔积液细菌学和胸腔积液化学这三个变量,将患者分为预后不良的四个不同风险级别:1级(极低风险)、2级(低风险)、3级(中度风险)和4级(高风险)。专家小组的共识意见支持对预后不良风险为中度(3级)或高度(4级)的患者进行引流,但不支持对预后不良风险为极低(1级)或低(2级)的患者进行引流。对医学文献进行了综述,以评估内科和外科治疗方法对预后不良风险为中度或高度的PPE患者的有效性。专家小组将PPE管理方法分为六类:未进行引流、治疗性胸腔穿刺术、胸腔置管引流术、纤维蛋白溶解剂、电视辅助胸腔镜手术(VATS)和手术(包括有或无胸膜剥脱术及肋骨切除术的开胸手术)。纤维蛋白溶解剂方法需要通过胸腔置管引流术给药,VATS包括术后胸腔置管引流术。手术可能包括同期肺切除术,且总是包括术后胸腔置管引流术。所有管理方法均包括对基础肺炎的适当治疗,包括全身使用抗生素。纳入专家小组综述文章的标准为:为≥20例成年PPE患者提供了足够的数据,以便评估至少一项相关结果(死亡或需要进行第二次干预来处理PPE);有合理的保证表明引流在临床上是合适的(接受引流的患者为3级或4级)且引流操作有充分描述;并且提供了原始数据。专家小组关于PPE管理的推荐强度基于以下方法:A级,结果一致的随机对照试验或置信区间(CI)较窄的单个随机对照试验;B级,对照队列和病例对照系列;C级,历史对照系列和病例系列;D级,未经明确严格评估的专家意见或基于生理学、基础研究或“第一原理”。
文献综述发现24篇文章符合专家小组进行全面综述的条件,其中19篇涉及PPE的主要管理方法,5篇涉及先前方法失败后的挽救方法。在涉及PPE主要管理方法的19篇文章中,有3篇随机对照试验、2篇历史对照系列和14篇病例系列。随机对照试验纳入的患者数量较少;在描述PPE主要管理方法结果的19篇文章中发现了方法学上的缺陷。对19篇关于主要管理方法的文章中每种管理方法的汇总数据,计算了出现两种相关结果(死亡和需要进行第二次干预来处理PPE)的患者比例及95%CI。(摘要)